<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3933">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055715</url>
  </required_header>
  <id_info>
    <org_study_id>ARO 2017-1</org_study_id>
    <nct_id>NCT03055715</nct_id>
  </id_info>
  <brief_title>Multicentric Retrospective Prognostic Evaluation of Tumor Volume and Their Changes in Radical Radiotherapy of Locally Advanced NSCLC</brief_title>
  <official_title>Multicentric Retrospective Prognostic Evaluation of Tumor Volume and Their Change in the Curative-intended, Radical Radiotherapy of Locally Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radiation Oncology Working Group of the German Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to retrospectively monitor the 'gross tumor volume' (GTV) before
      initiation of radiotherapy and its changes during radiotherapy and to correlate them with
      retrospectively recorded patient data, as well as with prognostic and therapeutic outcome
      after definite radiotherapy of locally advanced NSCLC in stage UICC III.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognostic relevance of the 'gross tumor volume' (GTV) in radiotherapy of advanced
      non-small-cell lung cancer (NSCLC) in stage III is adressed in a limited number of studies
      in the literature. The review article by Dubben et al., that comprises data until 1998,
      highlights the GTV as an important indicator and influencing factor for the therapeutic
      success after radiotherapy, albeit not being dominant over the T-stage (Dubben et al. 1988).
      In general, an increase in tumor volume correlates with a higher T-stage (Martel et al.
      1997), but no congruence can neccessarily be assumed between the tumor volume and the
      T-determinator. Since the TNM-classification is primarily surgical however, it also does not
      provide sufficient information for prognosis when surgical therapy is not the first choice.

      Available evidence suggests that the GTV in particular at the beginning of therapy acts as a
      statistically significant prognostic indicator regarding overall survival and / or local
      tumor control (Martel et al. 1997; Bradley et al. 2002; Basaki et al. 2006; Etiz et al.
      2002; Werner-Wasik et al. 2001; Wer-ner-Wasik et al. 2008; Stinchcombe et al. 2006;
      Dehing-Oberije et al. 2008; Willner et al. 2002; Ball et al. 2013). A direct comparison
      between different studies is, however, often hampered due to the large variation of
      measurement time points during therapy, as well as the employed definition of the tumor
      volume. For example, all studies include patients whose GTV was determined after
      (neoadjuvant) chemotherapy. In addition, three studies even combine the tumor volume of the
      primary tumor with affected lymph nodes (Etiz et al. 2002; Werner-Wasik et al. 2008;
      Dehing-Oberije et al. 2008). Furthermore, no agreements can be found in the literature
      concerning volume changes during therapy. Nonetheless, all studies report a volume reduction
      at the end of therapy, albeit not always significant. In a study containing 10 patients
      treated with helical Tomotherapy, the authors observed a relative median tumor reduction
      during therapy of 1.2% per day (0.6-2.3%) (Kupelian et al. 2005).

      The response of NSCLC to radiotherapy with or without chemotherapy is slow (Woodford et al.
      2007) with tumors reaching their maximum response or minimal volume after 5-11 months after
      exposure (Werner-Wasik et al. 2001). If the tumor volume is determined too early, i.e.
      directly after the end of therapy, the results can lead to misinterpretation resulting in an
      overestimation of the tumor volume or correspondingly an underestimation of the therapeutic
      response (Siker et al. 2006). According to Bell et al., the predictive value of tumor volume
      changes in the first 18 months after radiotherapy is of particular importance. During this
      time, a significantly increased mortality was observed for larger tumor volumes.

      Incorporation of a PET/CT in the context of the radiaton plan is advantageous with respect
      to the precise traget-volume definition and sparing of risk organs (Ruysscher et al. 2005;
      Nestle et al. 2006; Lavrenkov et al. 2005; van Baardwijk et al. 2007; Edet-Sanson et al.
      2012; Ruysscher und Kirsch 2010; As-hamalla et al. 2005; Bradley et al. 2004; van Baardwijk
      et al. 2006; Vanuytsel et al. 2000). The superiority of PET compared to stand-alone CT was
      also shown in two meta-analysis (Gould et al. 2001; Gould et al. 2003). The importance of
      the 'standardized uptake value' (SUV) or the metabolic tumor volume (MTV) as well as the
      change in these parameters during radiotherapy has been repeatedly demonstrated (Berghmans
      et al. 2008, Gillham et al. 2008; Zhang et al. 2011; van Elmpt et al. 2012; Edet-Sanson et
      al. 2012; van Baardwijk et al. 2007; Vera et al. 2014; Vanuytsel et al. 2000; Feifei Na et
      al. 2014; Lopez Guerra et al. 2012; Lee et al. 2007; Lee et al. 2012; Huang et al. 2011;
      Xiang et al. 2012). These studies show partly a statistically significant correlation
      between tumorale FDG-accumulation before, during or after radiotherapy, or the decreasing
      accumulation during radiotherapy, respectively, and the overall survival. The results,
      however, suffer from a large uncertainty regarding the distinct influence corresponding to
      the SUV. Other studies report a significantly weaker association of the SUV and survival
      (Hoang et al. 2008; IKUSHIMA et al. 2010; Lopez Guerra et al. 2012). Due to the dynamic
      variations in the SUV and MTV during radiotherapy, a change in the prognostic validity
      during radiotherapy can be assumed. According to van Elmpt and others, the FDG uptake during
      the second (van Elmpt et al. 2012; Zhang et al. 2011) or fifth week of exposure is crucial
      for survival (Edet-Sanson et al. 2012). Work by van Baardwijk et al. shows an increase in
      the SUV in some patients during the first week of therapy, which is explained by
      radiation-triggered inflammation and tumor-biological changes due to radiotherapy (van
      Baardwijk et al. 2007). The results demonstrate that the appearance of tumor necrosis during
      radiotherapy or changes in the metabolic tumor situation or oxygenation affect the SUV
      parameter crucially (Hoang et al. 2008, Huang et al. 2014; Huang et al. 2011). In this
      context, tumorhypoxia and the corresponding effects on the metabolism of glucose are of
      particularly importance: A hypoxia-simulated upregulation of the membranic glucose
      transporter with consecutive increase of cellular FDG uptage can lead to a false SUV value,
      calling for a combination of SUV or MTV with other prognostic parameters as well as
      hypoxia-specific imaging (FMISO-PET) (Ikushima et al. 2010, Berghmans et al. 2008).
      Consequently, the optimal timevpoint for carrying out a PET during / after radiotherapy is
      not well defined, especially when the protracted tumor response after completion of
      radiotherapy is taken into account, leaving the integration of additional PET measurements
      during radiotherapy exclusively to clinical studies.

      In conclusion, evidence from available literature regarding the prognostic and predictive
      value of tumor volume before and particularly its changes during radiotherapy of locally
      advanced NSCLC is conflicting and inconclusive. Currently available studies often include
      only a small number of patients with partly overlapping patient cohorts. Current data is
      additionally limited due to the highly heterogeneous GTV detection time points as well as
      the definition and detection methodology of tumor volumes.

      Based on the observation that a significant tumor volume reduction occurs during
      radiotherapy, a reevaluation of the tumor volume during radiotherapy could allow an
      adaptation of the target volumes with dose escalating in the tumor area, while at the same
      time, improving the protection of organs at risk.

      The prognostic or predictive significance of absolute tumor volumes or their change under
      radiotherapy is to be evaluated multicentrically and its integration into already existing
      prognostic models is to be multicentrically validated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (months)</measure>
    <time_frame>5 months</time_frame>
    <description>from the start of Radiotherapy until death / last seen during follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Basal Gross Tumor Volume (ml) before Radiotherapy (GTV1)</measure>
    <time_frame>5 months</time_frame>
    <description>as detected by initial planning CT or diagnostic CT before the start of RT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Gross Tumor Volume before Radiation Boost (GTV2)</measure>
    <time_frame>5 months</time_frame>
    <description>as detected in re-planning CT or CBCT before initiation of radiation boost</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Gross Tumor Volume Changes (delta GTV related to basal GTV)</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Non Small Cell Lung Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Locally advanced NSCLC-patients</arm_group_label>
    <description>Inoperable stage III (A and B) non-small-cell lung cancer (NSCLC) with indication for radical radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>No intervention in this retrospective study</description>
    <arm_group_label>Locally advanced NSCLC-patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Locally advanced, inoperable stage III (A and B) non-small-cell lung cancer without prior
        surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed NSCLC (Adeno / SCC) Stage UICC III A or B

          -  PET or PET-CT within for initial radiation planning

          -  completed curative-intended radiotherapy ± chemotherapy (achieved total dose ≥ 60 Gy
             normofractionated or ≥ 50 Gy hypofractionated)

        Exclusion Criteria:

          -  Stereotactic radiotherapy

          -  Second malignancy &lt;5 years before diagnosis of NSCLC

          -  Pleural effusion ipsilateral, extensive atelectasis ipsilateral
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Ostheimer, MD</last_name>
    <phone>+49345557</phone>
    <phone_ext>3432</phone_ext>
    <email>christian.ostheimer@uk-halle.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Medenwald, MD</last_name>
    <phone>+49345557</phone>
    <phone_ext>4027</phone_ext>
    <email>daniel.medenwald@uk-halle.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiooncology, Charité Campus Mitte und Campus Virchow Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Thieme, MD</last_name>
      <email>alexander-henry-thieme@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>David Kaul</last_name>
      <email>davidpkaul@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Thieme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Kaul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maike Trommer-Nestler, MD</last_name>
      <email>maike.trommer@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Kloock</last_name>
      <email>lisa.kloock@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Maike Trommer-Nestler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Kloock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Baues, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadja Ebert, MD</last_name>
      <email>Nadja.Ebert@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Nadja Ebert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Düsseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Haussmann, MD</last_name>
      <email>Jan.Haussmann@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Jan Haussmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonia Ziegler</last_name>
      <email>Sonia.Ziegler@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Sonia Ziegler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Ostheimer, MD</last_name>
      <email>christian.ostheimer@uk-halle.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Medenwald, MD</last_name>
      <email>daniel.medenwald@uk-halle.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ostheimer Ostheimer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Medenwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Gauer, Dr.rer.nat.</last_name>
      <email>t.gauer@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Yvonne Goy</last_name>
      <email>y.goy@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Tobias Gauer, Dr.rer.nat.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Goy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Henkenberens, MD</last_name>
      <email>henkenberens.christoph@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Henkenberens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Krug, MD</last_name>
      <email>David.Krug@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Schmitt, MD</last_name>
      <email>Daniela.Schmitt@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>David Krug, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Schmitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias A Mäurer, MD</last_name>
      <email>matthias.maeurer@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Mäurer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René Baumann, MD</last_name>
      <email>Rene.Baumann@uksh.de</email>
    </contact>
    <investigator>
      <last_name>René Baumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology Lübeck</name>
      <address>
        <city>Lubeck Hansestadt</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lukas Kaesmann, MD</last_name>
      <email>lkaesmann@googlemail.com</email>
    </contact>
    <investigator>
      <last_name>Lukas Kaesmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Giordano, MD</last_name>
      <email>Frank.Giordano@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>L Sauter</last_name>
      <email>Lisa.sautter@umm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Frank Giordano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>L Sauter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Munich (LMU, Campus Großhadern)</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Fleischmann, MD</last_name>
      <email>Daniel.Fleischmann@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Maximilian Niyazi, MD</last_name>
      <email>Maximilian.Niyazi@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Fleischmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maximilian Niyazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Munich (TUM)</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Dobiasch, MD</last_name>
      <email>sophie.dobiasch@tum.de</email>
    </contact>
    <investigator>
      <last_name>Sophie Dobiasch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Strahlentherapie, St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cédric M Panje, MD</last_name>
      <email>cmpanje@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Cédric M Panje, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>February 14, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Christian Ostheimer, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>young DEGRO</keyword>
  <keyword>tumor volume</keyword>
  <keyword>lung cancer</keyword>
  <keyword>radiochemotherapy</keyword>
  <keyword>prognostic factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
